Brentuximab Vedotin Drug Aliquot | Anti-CD30 | Therapeutic ADC

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Brentuximab Vedotin are now available as research consumables.

Brentuximab vedotin drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Brentuximab vedotin drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Brentuximab Vedotin Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Adcetris® / Brentuximab Vedotin Reference Product

Drug nameAdcetris®
INNBrentuximab Vedotin
API typeBrentuximab Vedotin is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody (recombinant chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE)
Pharmacotherapeutic group
Antineoplastic agents
ATC code
Target of antibody
General functionThe monoclonal antibody delivers monomethyl auristatin E to the CD30-positive cancer cells. The cytotoxic molecule then enters the cancer cells and stops them from dividing, and the cancer cells eventually die.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Brentuximab vedotin is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The primary objective was to evaluate the effect of brentuximab vedotin on cardiac ventricular re-polarization and the predefined primary analysis was the change in QTc from baseline to multiple time points in Cycle 1.
The upper 90% confidence interval (CI) around the mean effect on QTc was < 10 msec at each of the Cycle 1 and Cycle 3 post-baseline time points. These data indicate the absence of clinically relevant QT prolongation due to brentuximab vedotin administered at a dose of 1.8 mg/kg every 3 weeks in patients with CD30-expressing malignancies.
Original license holder
Takeda Pharma A/S
Marketing authorisation numbers
Marketing authorisation holder
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Name of the manufacturer of the biological active substance
Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Name and address of the manufacturer(s) responsible for batch releaseTakeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Citric acid monohydrate
Sodium citrate dihydrate
α,α-Trehalose dihydrate
Polysorbate 80

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.